The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives
Abstract
:1. Introduction
2. Materials and Methods
3. Clinical Implications of miRNA
3.1. Diagnostic Performance
3.2. Treatment Response and Clinical Decision Making
3.2.1. Surgical Treatment
3.2.2. Chemotherapy
3.2.3. Active Surveillance and Residual Disease Detection
4. Future Perspective
5. Strengths and Limitations
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Park, J.S.; Kim, J.; Elghiaty, A.; Ham, W.S. Recent global trends in testicular cancer incidence and mortality. Medicine 2018, 97, e12390. [Google Scholar] [CrossRef] [PubMed]
- Ghazarian, A.A.; Trabert, B.; Devesa, S.S.; McGlynn, K.A. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology 2015, 3, 13–18. [Google Scholar] [CrossRef] [PubMed]
- Patrikidou, A.; Cazzaniga, W.; Berney, D.; Boormans, J.; de Angst, I.; Di Nardo, D.; Fankhauser, C.; Fischer, S.; Gravina, C.; Gremmels, H.; et al. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur. Urol. 2023, 84, 289–301. [Google Scholar] [CrossRef] [PubMed]
- Singh, R.; Fazal, Z.; Bikorimana, E.; Boyd, R.I.; Yerby, C.; Tomlin, M.; Baldwin, H.; Shokry, D.; Corbet, A.K.; Shahid, K.; et al. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy. Mol. Oncol. 2022, 16, 683–698. [Google Scholar] [CrossRef] [PubMed]
- Regouc, M.; Belge, G.; Lorch, A.; Dieckmann, K.-P.; Pichler, M. Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer. Cancers 2020, 12, 749. [Google Scholar] [CrossRef] [PubMed]
- De Martino, M.; Chieffi, P.; Esposito, F. miRNAs and Biomarkers in Testicular Germ Cell Tumors: An Update. Int. J. Mol. Sci. 2021, 22, 1380. [Google Scholar] [CrossRef] [PubMed]
- Soleimani, M.; Kollmannsberger, C.; Nappi, L. Emerging Role of Biomarkers in Testicular Germ Cell Tumors. Curr. Oncol. Rep. 2022, 24, 437–442. [Google Scholar] [CrossRef]
- Aveta, A.; Cilio, S.; Contieri, R.; Spena, G.; Napolitano, L.; Manfredi, C.; Franco, A.; Crocerossa, F.; Cerrato, C.; Ferro, M.; et al. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 10846. [Google Scholar] [CrossRef]
- Goodall, G.J.; Wickramasinghe, V.O. RNA in cancer. Nat. Rev. Cancer 2021, 21, 22–36. [Google Scholar] [CrossRef]
- Martin, F.C.; Conduit, C.; Loveland, K.L.; Thomas, B.; Lewin, J.; Tran, B. Genetics of testicular cancer: A review. Curr. Opin. Urol. 2022, 32, 481–487. [Google Scholar] [CrossRef]
- Jafari, A.; Karimabadi, K.; Rahimi, A.; Rostaminasab, G.; Khazaei, M.; Rezakhani, L.; Jouybari, T.A. The Emerging Role of Exosomal miRNAs as Biomarkers for Early Cancer Detection: A Comprehensive Literature Review. Technol. Cancer Res. Treat. 2023, 22, 15330338231205999. [Google Scholar] [CrossRef] [PubMed]
- Pantos, K.; Grigoriadis, S.; Tomara, P.; Louka, I.; Maziotis, E.; Pantou, A.; Nitsos, N.; Vaxevanoglou, T.; Kokkali, G.; Agarwal, A.; et al. Investigating the Role of the microRNA-34/449 Family in Male Infertility: A Critical Analysis and Review of the Literature. Front. Endocrinol. 2021, 12, 709943. [Google Scholar] [CrossRef] [PubMed]
- Novotny, G.W.; Belling, K.C.; Bramsen, J.B.; Nielsen, J.E.; Bork-Jensen, J.; Almstrup, K.; Sonne, S.B.; Kjems, J.; Meyts, E.R.-D.; Leffers, H. MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocr.-Relat. Cancer 2012, 19, 365–379. [Google Scholar] [CrossRef] [PubMed]
- Bing, Z.; Master, S.R.; Tobias, J.W.; Baldwin, D.A.; Xu, X.W.; Tomaszewski, J.E. MicroRNA expression profiles of seminoma from paraffin-embedded formalin-fixed tissue. Virchows Arch. 2012, 461, 663–668. [Google Scholar] [CrossRef]
- Gillis, A.; Stoop, H.; Hersmus, R.; Oosterhuis, J.; Sun, Y.; Chen, C.; Guenther, S.; Sherlock, J.; Veltman, I.; Baeten, J.; et al. High-throughput microRNAome analysis in human germ cell tumours. J. Pathol. 2007, 213, 319–328. [Google Scholar] [CrossRef] [PubMed]
- Almstrup, K.; Lobo, J.; Mørup, N.; Belge, G.; Meyts, E.R.-D.; Looijenga, L.H.J.; Dieckmann, K.-P. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat. Rev. Urol. 2020, 17, 201–213. [Google Scholar] [CrossRef] [PubMed]
- Vilela-Salgueiro, B.; Barros-Silva, D.; Lobo, J.; Costa, A.L.; Guimarães, R.; Cantante, M.; Lopes, P.; Braga, I.; Oliveira, J.; Henrique, R.; et al. Germ cell tumour subtypes display differential expression of microRNA371a-3p. Philos. Trans. R. Soc. B Biol. Sci. 2018, 373, 20170338. [Google Scholar] [CrossRef]
- Dieckmann, K.-P.; Spiekermann, M.; Balks, T.; Ikogho, R.; Anheuser, P.; Wosniok, W.; Loening, T.; Bullerdiek, J.; Belge, G. MicroRNA miR-371a-3p—A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid. Urol. Int. 2016, 97, 76–83. [Google Scholar] [CrossRef]
- Dieckmann, K.P.; Radtke, A.; Spiekermann, M.; Balks, T.; Matthies, C.; Becker, P.; Ruf, C.; Oing, C.; Oechsle, K.; Bokemeyer, C.; et al. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. Eur. Urol. 2017, 71, 213–220. [Google Scholar] [CrossRef]
- van Agthoven, T.; Looijenga, L.H.J. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget 2017, 8, 58037–58049. [Google Scholar] [CrossRef]
- Syring, I.; Bartels, J.; Holdenrieder, S.; Kristiansen, G.; Müller, S.C.; Ellinger, J. Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell Cancer. J. Urol. 2015, 193, 331–337. [Google Scholar] [CrossRef] [PubMed]
- Dieckmann, K.-P.; Radtke, A.; Geczi, L.; Matthies, C.; Anheuser, P.; Eckardt, U.; Sommer, J.; Zengerling, F.; Trenti, E.; Pichler, R.; et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J. Clin. Oncol. 2019, 37, 1412–1423. [Google Scholar] [CrossRef] [PubMed]
- Gillis, A.J.; Rijlaarsdam, M.A.; Eini, R.; Dorssers, L.C.; Biermann, K.; Murray, M.J.; Nicholson, J.C.; Coleman, N.; Dieckmann, K.-P.; Belge, G.; et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: A proof of principle. Mol. Oncol. 2013, 7, 1083–1092. [Google Scholar] [CrossRef]
- Nappi, L.; Thi, M.; Lum, A.; Huntsman, D.; Eigl, B.J.; Martin, C.; O’neil, B.; Maughan, B.L.; Chi, K.; So, A.; et al. Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J. Clin. Oncol. 2019, 37, 3090–3098. [Google Scholar] [CrossRef] [PubMed]
- Badia, R.R.; Abe, D.; Wong, D.; Singla, N.; Savelyeva, A.; Chertack, N.; Woldu, S.L.; Lotan, Y.; Mauck, R.; Ouyang, D.; et al. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. J. Urol. 2021, 205, 137–144. [Google Scholar] [CrossRef] [PubMed]
- Lobo, J.; Gillis, A.J.M.; van den Berg, A.; Dorssers, L.C.J.; Belge, G.; Dieckmann, K.-P.; Roest, H.P.; Van Der Laan, L.J.W.; Gietema, J.; Hamilton, R.J.; et al. Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells 2019, 8, 1637. [Google Scholar] [CrossRef] [PubMed]
- Leão, R.; Albersen, M.; Looijenga, L.H.; Tandstad, T.; Kollmannsberger, C.; Murray, M.J.; Culine, S.; Coleman, N.; Belge, G.; Hamilton, R.J.; et al. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. Eur. Urol. 2021, 80, 456–466. [Google Scholar] [CrossRef]
- Radtke, A.; Cremers, J.F.; Kliesch, S.; Riek, S.; Junker, K.; Mohamed, S.A.; Anheuser, P.; Belge, G.; Dieckmann, K.P. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p? J. Cancer Res. Clin. Oncol. 2017, 143, 2383–2392. [Google Scholar] [CrossRef]
- Nappi, L.; Nichols, C. MicroRNAs as Biomarkers for Germ Cell Tumors. Urol. Clin. North Am. 2019, 46, 449–457. [Google Scholar] [CrossRef]
- van Agthoven, T.; Eijkenboom, W.M.H.; Looijenga, L.H.J. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. Cell. Oncol. 2017, 40, 379–388. [Google Scholar] [CrossRef]
- Murray, M.J.; Halsall, D.J.; Hook, C.E.; Williams, D.M.; Nicholson, J.C.; Coleman, N.; Gong, Y.; Sweet, W.; Duh, Y.-J.; Greenfield, L.; et al. Identification of MicroRNAs From the miR-371∼373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors. Am. J. Clin. Pathol. 2011, 135, 119–125. [Google Scholar] [CrossRef] [PubMed]
- Dieckmann, K.-P.; Spiekermann, M.; Balks, T.; Flor, I.; Löning, T.; Bullerdiek, J.; Belge, G. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br. J. Cancer 2012, 107, 1754–1760. [Google Scholar] [CrossRef] [PubMed]
- Murray, M.J.; Bell, E.; Raby, K.L.; Rijlaarsdam, A.M.; Gillis, A.J.M.; Looijenga, L.H.J.; Brown, H.; Destenaves, B.; Nicholson, J.C.; Coleman, N. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br. J. Cancer 2016, 114, 151–162. [Google Scholar] [CrossRef] [PubMed]
- Lafin, J.T.; Singla, N.; Woldu, S.L.; Lotan, Y.; Lewis, C.M.; Majmudar, K.; Savelyeva, A.; Kapur, P.; Margulis, V.; Strand, D.W.; et al. Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. Eur. Urol. 2020, 77, 290–292. [Google Scholar] [CrossRef]
- Leão, R.; van Agthoven, T.; Figueiredo, A.; Jewett, M.A.; Fadaak, K.; Sweet, J.; Ahmad, A.E.; Anson-Cartwright, L.; Chung, P.; Hansen, A.; et al. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. J. Urol. 2018, 200, 126–135. [Google Scholar] [CrossRef] [PubMed]
- Lafin, J.T.; Bagrodia, A.; Woldu, S.; Amatruda, J.F. New insights into germ cell tumor genomics. Andrology 2019, 7, 507–515. [Google Scholar] [CrossRef]
- Mego, M.; van Agthoven, T.; Gronesova, P.; Chovanec, M.; Miskovska, V.; Mardiak, J.; Looijenga, L.H. Clinical utility of plasma miR-371a-3p in germ cell tumors. J. Cell. Mol. Med. 2019, 23, 1128–1136. [Google Scholar] [CrossRef] [PubMed]
- Terbuch, A.; Adiprasito, J.B.; Stiegelbauer, V.; Seles, M.; Klec, C.; Pichler, G.P.; Resel, M.; Posch, F.; Lembeck, A.L.; Stöger, H.; et al. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. Int. J. Mol. Sci. 2018, 19, 3130. [Google Scholar] [CrossRef]
- Lobo, J.; Leão, R.; Gillis, A.J.; Berg, A.v.D.; Anson-Cartwright, L.; Atenafu, E.G.; Kuhathaas, K.; Chung, P.; Hansen, A.; Bedard, P.L.; et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur. Urol. Oncol. 2021, 4, 483–491. [Google Scholar] [CrossRef]
- Frazier, L.A. Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients WITH Germ Cell Tumors (ClinicalTrials.gov ID NCT0306718)1. Available online: https://www.clinicaltrials.gov/study/NCT03067181#publications (accessed on 5 October 2023).
- Plaza, X.R.; van Agthoven, T.; Meijer, C.; van Vugt, M.A.T.M.; de Jong, S.; Gietema, J.A.; Looijenga, L.H.J. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy. Cells 2019, 8, 1221. [Google Scholar] [CrossRef]
- Nappi, L.; Thi, M.; Adra, N.; Hamilton, R.J.; Leao, R.; Lavoie, J.M.; Soleimani, M.; Eigl, B.J.; Chi, K.; Gleave, M.; et al. Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. Eur. Urol. 2020, 79, 16–19. [Google Scholar] [CrossRef]
- Kenigsberg, A.P.; Lafin, J.T.; Meng, X.; Abe, D.; Savalyeva, A.; Singla, N.; Woldu, S.; Lotan, Y.; Kapur, P.; Margulis, V.; et al. Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND). J. Clin. Oncol. 2020, 38 (Suppl. S6), 416. [Google Scholar] [CrossRef]
- Belge, G.; Grobelny, F.; Mattheis, C.; Radtke, A.; Dieckmann, K.P. Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma. Vivo 2020, 34, 163–168. [Google Scholar] [CrossRef]
- Nichols, C.R. A Study of miRNA 371 in Patients With Germ Cell Tumors (ClinicalTrials.gov ID: NCT04435756), SWOG Cancer Research Network. Available online: https://clinicaltrials.gov/study/NCT04435756#collaborators-and-investigators (accessed on 5 October 2023).
- Conduit, C.; Grimison, P.S.; Lewin, J.H.; Hansen, A.R.; Lynam, J.F.; Weickhardt, A.J.; Parente, P.; Campbell, D.C.; Hong, W.; Marx, G.M.; et al. CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906. J. Clin. Oncol. 2023, 41 (Suppl. S16), TPS5100. [Google Scholar] [CrossRef]
- Bagrodia, A.; Savelyeva, A.; Lafin, J.T.; Speir, R.W.; Chesnut, G.T.; Frazier, A.L.; Woldu, S.L.; Margulis, V.; Murray, M.J.; Amatruda, J.F.; et al. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. BJU Int. 2021, 128, 57–64. [Google Scholar] [CrossRef] [PubMed]
miRNA | Detection Site | Expression | Role | Clinical Function |
---|---|---|---|---|
miR-302 [13,14,15] | Plasma GCNIS and TGCT tissues | ↑ | ||
miR-367-3p [13,14,15,32] | Plasma GCNIS and TGCT tissues | ↑ | Diagnosis Prognosis | Higher in patients relapsing after chemotherapy/refractory disease |
miR-302abc/200c [23] | Plasma | ↑ | Diagnosis | |
miR-371-3/367 [23] | Plasma | ↑ | Diagnosis | |
miR-371-3 [27] | Plasma GCNIS and TGCT tissues | ↑ or ↓ | Tumour size | |
miR-371a-3p [32,35,41] | Plasma and hydrocele fluid of patients with TGCT | ↑ or ↓ | Diagnosis Prognosis | Increases in presence of GCT/residual disease Decreases after radical orchiectomy/chemotherapy Higher in patients relapsing after chemotherapy |
miR-372 [31,32,33] | Plasma | ↓ | Prognosis | Decreased levels in response to chemotherapy Disease relapse |
miR-373-3p [32,35] | Plasma | ↑ | Prognosis | Higher in patients relapsing after chemotherapy |
miR-375 [42,43,44] | Plasma | ↑ | Diagnosis | Possible biomarker for teratoma (combined with miR-371) Higher in patients with residual disease |
miR-371 [45,46] | Plasma | ↓ | Diagnosis | Possible biomarker for teratoma (combined with miR-375) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ditonno, F.; Franco, A.; Manfredi, C.; Fasanella, D.; Abate, M.; La Rocca, R.; Crocerossa, F.; Iossa, V.; Falagario, U.G.; Cirillo, L.; et al. The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives. Medicina 2023, 59, 2033. https://doi.org/10.3390/medicina59112033
Ditonno F, Franco A, Manfredi C, Fasanella D, Abate M, La Rocca R, Crocerossa F, Iossa V, Falagario UG, Cirillo L, et al. The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives. Medicina. 2023; 59(11):2033. https://doi.org/10.3390/medicina59112033
Chicago/Turabian StyleDitonno, Francesco, Antonio Franco, Celeste Manfredi, Daniela Fasanella, Marco Abate, Roberto La Rocca, Fabio Crocerossa, Vincenzo Iossa, Ugo Giovanni Falagario, Luigi Cirillo, and et al. 2023. "The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives" Medicina 59, no. 11: 2033. https://doi.org/10.3390/medicina59112033
APA StyleDitonno, F., Franco, A., Manfredi, C., Fasanella, D., Abate, M., La Rocca, R., Crocerossa, F., Iossa, V., Falagario, U. G., Cirillo, L., Altieri, V. M., Di Mauro, E., Crocetto, F., Barone, B., Cilio, S., Pandolfo, S. D., Aveta, A., Mirone, V., Franzese, C. A., ... Napolitano, L. (2023). The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives. Medicina, 59(11), 2033. https://doi.org/10.3390/medicina59112033